This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Here's Why DaVita HealthCare (DVA) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract
by Zacks Equity Research
Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 14.29% and 0.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Astrana Health, Inc. (ASTH) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -39.13% and 2.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Revenue Cycle Operations Drive DVA Stock Before Q1 Earnings?
by Zacks Equity Research
Continued strength in revenue cycle operations is likely to have boosted DaVita's top line in the first quarter despite supply challenges weighing on its performance.
DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $143.96, moving +0.94% from the previous trading session.
LifeStance Health Group (LFST) Reports Break-Even Earnings for Q1
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 100% and 0.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Beats Q1 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 6.77% and 0.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $140.44 in the latest trading session, marking a -0.78% move from the prior day.
DaVita HealthCare (DVA) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the latest trading session, DaVita HealthCare (DVA) closed at $134.97, marking a +1.1% move from the previous day.
DaVita HealthCare (DVA) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $140.03, signifying a -1.04% move from its prior day's close.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and Addus HomeCare
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.
DaVita HealthCare (DVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $153.36 in the latest trading session, marking a +0.33% move from the prior day.
4 Stocks to Watch in a Dynamic Outpatient Home Health Industry
by Debanjana Dey
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.
DaVita HealthCare (DVA) Stock Moves -0.36%: What You Should Know
by Zacks Equity Research
In the most recent trading session, DaVita HealthCare (DVA) closed at $153.73, indicating a -0.36% shift from the previous trading day.
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw DaVita HealthCare (DVA) settling at $151.91, representing a -0.69% change from its previous close.
Why Is Chemed (CHE) Up 4.5% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, DaVita HealthCare (DVA) closed at $151.37, indicating a +0.39% shift from the previous trading day.
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play
by Debanjana Dey
DVA's stable core business and global expansion are offset by rising labor costs and declining commercial mix, creating a mixed outlook for investors.
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
DaVita HealthCare (DVA) reachead $150.78 at the closing of the latest trading day, reflecting a +0.25% change compared to its last close.
DaVita HealthCare (DVA) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw DaVita HealthCare (DVA) settling at $149.83, representing a +0.31% change from its previous close.
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $141.12, moving -1.06% from the previous trading session.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
DVA Stock Down in Pre-Market Despite Q4 Earnings Beat, Margins Expand
by Zacks Equity Research
Robust segmental revenues drive DaVita's fourth-quarter 2024 performance despite a per-day decrease of the total U.S. dialysis treatments on a sequential basis.